WSR 16-11-059 PERMANENT RULES DEPARTMENT OF HEALTH (Pharmacy Quality Assurance Commission) [Filed May 13, 2016, 12:49 p.m., effective June 13, 2016] Effective Date of Rule: Thirty-one days after filing.
Purpose: WAC 246-887-040 Designation of nonnarcotic stimulant drugs for purposes of RCW 69.50.402 (1)(c) and 246-887-045 Prescribing, dispensing, or administering of Schedule II nonnarcotic stimulants, the commission adopted rules adding Lisdexamfetamine to the list of Schedule II nonnarcotic stimulants a practitioner may lawfully prescribe, order, dispense, administer, supply, or give to a person for the treatment of binge eating disorder in adults.
Citation of Existing Rules Affected by this Order: Amending WAC 246-887-040 and 246-887-045.
Adopted under notice filed as WSR 16-02-016 on December 28, 2015.
A final cost-benefit analysis is available by contacting Doreen Beebe, Department of Health, Pharmacy Quality Assurance Commission, P.O. Box 47852, Olympia, WA 98501, phone (360) 236-4834, fax (360) 236-2260, e-mail doreen.beebe@doh.wa.gov.
Number of Sections Adopted in Order to Comply with Federal Statute: New 0, Amended 0, Repealed 0; Federal Rules or Standards: New 0, Amended 0, Repealed 0; or Recently Enacted State Statutes: New 0, Amended 0, Repealed 0.
Number of Sections Adopted at Request of a Nongovernmental Entity: New 0, Amended 2, Repealed 0.
Number of Sections Adopted on the Agency's Own Initiative: New 0, Amended 0, Repealed 0.
Number of Sections Adopted in Order to Clarify, Streamline, or Reform Agency Procedures: New 0, Amended 0, Repealed 0.
Number of Sections Adopted Using Negotiated Rule Making: New 0, Amended 0, Repealed 0; Pilot Rule Making: New 0, Amended 0, Repealed 0; or Other Alternative Rule Making: New 0, Amended 2, Repealed 0.
Date Adopted: March 3, 2016.
Tim Lynch, PharmD, Chair
Pharmacy Quality Assurance Commission
AMENDATORY SECTION (Amending WSR 92-04-029, filed 1/28/92, effective 2/29/92)
WAC 246-887-040 Designation of nonnarcotic stimulant drugs for purposes of RCW 69.50.402 (1)(c).
The ((board of)) pharmacy quality assurance commission hereby designates, the following Schedule II controlled substances as nonnarcotic stimulants for purposes of RCW 69.50.402 (((a)(3) [69.50.402 (1)(c)])) (1)(c):
(1) Amphetamine sulfate in any of its generic forms.
(2) Dextroamphetamine sulfate in any of its generic forms and under the following brand names:
(a) Dexedrine (SKF);
(b) Dexedrine spansules (SKF).
(3) Dextroamphetamine HCL in any of its generic forms.
(4) Dextroamphetamine tannate in any of its generic forms.
(5) Methamphetamine HCL (Desoxyephedrine HCL) in any of its generic forms and under the following brand name:
Desoxyn (Abbott).
(6) Amphetamine complex in any of its generic forms and under the following brand names:
(a) Biphetamine 12 1/2 (Pennwalt);
(b) Biphetamine 20 (Pennwalt).
(7) Combined amphetamines sold under the following brand names:
Obetrol-10 and 20 (Obetrol).
(8) Phenmetrazine HCL in any of its generic forms and under the following brand name:
(((a))) Preludin (Boehringer-Ingelheim).
(9) Methylphenidate HCL in any of its generic forms and under the following brand name:
(((a))) Ritalin (Ciba).
(10) Lisdexamfetamine in any of its generic forms and under the following brand name:
Vyvanse.
AMENDATORY SECTION (Amending WSR 03-04-045, filed 1/28/03, effective 2/28/03)
WAC 246-887-045 Prescribing, dispensing, or administering of Schedule II nonnarcotic stimulants.
The Schedule II stimulants listed in WAC 246-887-040 may be prescribed, dispensed, or administered to patients for the following disease states or conditions:
(2) Multiple sclerosis; and
(3) Moderate to severe binge eating disorder in adults.
|